Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document

In patients treated with macitentan (Opsumit®, Actelion Pharmaceuticals Ltd., Basel, Switzerland) for pulmonary arterial hypertension (PAH), prevention and/or effective management of treatment-related adverse events may improve adherence. However, management of these adverse events can be challengin...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahaghi, Franck F., Alnuaimat, Hassan M., Awdish, Rana L.A., Balasubramanian, Vijay P., Bourge, Robert C., Burger, Charles D., Butler, John, Cauthen, C. Gregory, Chakinala, Murali M., deBoisblanc, Bennett P., Eggert, Michael S., Engel, Peter, Feldman, Jeremy, McConnell, J. Wesley, Park, Myung, Sager, Jeffrey S., Sood, Namita, Palevsky, Harold I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841904/
https://www.ncbi.nlm.nih.gov/pubmed/28671484
http://dx.doi.org/10.1177/2045893217721695

Ejemplares similares

Ejemplares similares